🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 91 of 173

  1. US 9241998

    Methods and compositions for treatment of cancer using oncolytic RSV activity

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9241999

    Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 9241976

    Use of HDL-related molecules to treat and prevent proinflammatory conditions

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 9243281

    Neuroprotective chemicals and methods for identifying and using same

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 9243055

    HERV-K antigens, antibodies, and methods

    Expires Mon Jan 21 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 9238044

    Alkali-free bioactive glass composition

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 9238041

    Methods and compositions for regulating RNA import into mitochondria

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 9238653

    Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase

    Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 9233162

    High affinity VEGF-receptor antagonists

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 9234078

    Conjugated gold nanoparticles

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 9234017

    Aquaporin-4 peptide compositions and methods of use thereof

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 9233164

    Water soluble fullerene formulations and methods of use thereof

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 9233131

    Mutant adeno-associated virus virions and methods of use thereof

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 9233121

    Compositions and methods for the treatment of cancer

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9233095

    Small molecule RNase inhibitors and methods of use

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9233085

    Topical application of AMPK activators for pharmacological prevention of chronic pain

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 9233068

    Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 9233926

    Compounds for stem cell differentiation

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 9233086

    Inhibition of WDR5 interaction with its binding partners

    Expires Mon Jan 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 9228172

    Inducible regulatory T-cell generation for hematopoietic transplants

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 9228001

    Mutants of cholesterol-dependent cytolysins and uses thereof

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 9228007

    Recombinant human progenitor cells, engineered human thymocytes, and engineered human T cells

    Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 9220772

    Anti-tumor antigen antibodies and methods of use

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 9220730

    Methods of treating ischemic spasticity

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 9220729

    Ameliorating nervous systems disorders

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 9220676

    Injectable in-situ crosslinked hydrogel and methods of making and using thereof

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 9220685

    Hollow silica nanospheres and methods of making same

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 9221800

    Isoxazole treatments for diabetes

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 9221772

    Synthesis of syrbactin proteasome inhibitors

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 9220733

    Solubilization of antigen components for removal from tissues

    Expires Mon Dec 24 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 9217007

    Platinum anticancer agents

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 9216220

    Compositions and methods for thermo-sensitive nanoparticles and magnetic nanoparticles

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 9217040

    Therapeutic antibodies against ROR-1 protein and methods for use of same

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 9216983

    Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 9216993

    Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 9216198

    Compositions and medical devices for controlled release of nitric oxide and methods of production thereof

    Expires Mon Dec 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 9212218

    Vmp-like sequences of pathogenic Borrelia

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 9212212

    Targeting complement factor H for treatment of diseases

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 9211419

    Treatments of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 9211328

    Modulation of NKG2D for prolonging survival of a hematopoietic graft

    Expires Mon Dec 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 9205131

    Use of IL-17D for the treatment and prevention of cancers

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 9205048

    Controlled release antimicrobial compositions and methods for the treatment of otic disorders

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 9206208

    Phosphonate compounds

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 9206423

    Methods of modulating compliance of the trabecular meshwork

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 9205119

    Neuroprotective compositions and methods

    Expires Mon Dec 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 9198842

    Multicomponent glasses for use in personal care products

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 9200091

    Bovine milk oligosaccharides

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 9200068

    Compositions and methods related to tauopathy

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.